Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Corporate venture investors stay strong
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
Newamsterdam braves the Spac track
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
Private equity gets serious about drug development
Venture capital has the brains, private equity has the books – can they make lots of money?
The retrenchment begins for venture funding
The gloomy climate for biotech is now taking its toll on private companies too.
To back, or back away from, digital health?
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
